SCHEMBL3574175

SCHEMBL3574175

Cc1ccc(-c2ccc3c(c2)/C(=C/Nc2ccc(N4CCN(C)CC4)cc2)C(=O)NC3=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 3/20 0.43
NPC1 O15118 2/20 0.42
RAB9A P51151 2/20 0.42
RPS6KA3 P51812 1/20 0.42
TNK2 Q07912 1/20 0.41
CSF1R P07333 1/20 0.40
MAP4K1 Q92918 1/20 0.38
OTUD7B Q6GQQ9 2/20 0.38
ASIC3 Q9UHC3 1/20 0.37
DYRK3 O43781 2/20 0.37
CLK1 P49759 2/20 0.37
CLK2 P49760 2/20 0.37
CLK3 P49761 2/20 0.37
GSK3B P49841 2/20 0.37
DYRK1A Q13627 2/20 0.37
DYRK2 Q92630 2/20 0.37
CLK4 Q9HAZ1 2/20 0.37
DYRK1B Q9Y463 2/20 0.37
PIM1 P11309 1/20 0.37
CSNK2A2 P19784 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3574178 1.00 MAPKAPK2 (0.43) MAPKAPK2NPC1RAB9ARPS6KA3TNK2
SCHEMBL3574781 0.92 MAP4K1 (0.43) MAPKAPK2NPC1RAB9ATNK2CSF1R
SCHEMBL3573755 0.92 MAP4K1 (0.43) MAPKAPK2NPC1RAB9ATNK2CSF1R
SCHEMBL3573753 0.92 MAP4K1 (0.43) MAPKAPK2NPC1RAB9ATNK2CSF1R
SCHEMBL3574786 0.92 MAP4K1 (0.43) MAPKAPK2NPC1RAB9ATNK2CSF1R
SCHEMBL3565586 0.91 MAPKAPK2 (0.46) MAPKAPK2NPC1RAB9ARPS6KA3TNK2
SCHEMBL3565589 0.91 MAPKAPK2 (0.46) MAPKAPK2NPC1RAB9ARPS6KA3TNK2
SCHEMBL3564117 0.91 MAPKAPK2 (0.44) MAPKAPK2RAB9ACSF1ROTUD7BALK
SCHEMBL3564115 0.91 MAPKAPK2 (0.44) MAPKAPK2RAB9ACSF1ROTUD7BALK
SCHEMBL3574825 0.91 MAPKAPK2 (0.44) MAPKAPK2NPC1RAB9ARPS6KA3CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US claimed
EP-1963273-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2008-09-03 EP claimed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US claimed
WO-2007075783-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR WYETH (US) 2007-07-05 WO claimed
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US disclosed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof SULT1E1, RECQL, HAX1 MAPKAPK2 4491/4885NPC1 538/4885RAB9A 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.